Skip to Content
 

VICC toll-free number 1-877-936-8422

Lung and Thoracic Cancers

Clinical Trials for Lung Cancers

39 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Basic Science

Melanoma
Non Small Cell

VICCMEL15137

07/21/2015

Characterizing the Cardiometabolic Implications of Immune Therapy

Basic Science

Lung
Non Small Cell

VICCTHO0547

12/19/2005

Molecular Fingerprints in Lung Cancer: Predicting Tumor Response to Therapy (SPORE)

Basic Science

Lung
Non Small Cell
Small Cell

VICCTHO0398

12/04/2003

Molecular Predictors of Lung Cancer Behavior. (SPORE)

Basic Science

Lung
Non Small Cell

VICCTHO0136

05/01/2001

Molecular Fingerprinting of Lung Cancer (SPORE)

Other

Lung

VICCTHO15123

05/20/2016

The PERCEPTA Registry

Other

Lung

VICCTHO15102

01/05/2016

Physical Activity Monitors for Valuable Endpoints in Malignant Pleural Effusions: the MOVE-MPE trial (pilot)

Other

Lung

VICCTHO1555

11/18/2015

A Case-Control Study to Verify Diagnostic Performance of AminoIndex Technology

Other

Lung
Non Small Cell

ECOGTHOA151216

09/17/2015

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Other

Lung

VICCTHO1496

04/03/2015

Lung Cancer Screening Program at VICC: Correlative Study

Other

Lung
Miscellaneous
Small Cell

VICCMD1494

10/31/2014

Specimen Collection under Clinical Protocol 06-C-0213 for Generation of Patient-Derived Models

Treatment

Lung
Non Small Cell

VICCTHO1614

08/05/2016

A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer

Treatment

Breast
Lung
Non Small Cell
Ovarian
Pancreatic

VICCPHI1671

08/02/2016

A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors

Treatment

Adrenocortical
Lung
Sarcoma
Wilms / Other Kidney (Pediatrics)

COGADVL1522

08/02/2016

A Phase 2 Study of IMGN901 (Lorvotuzumab Mertansine; IND# 126953, NSC# 783609) in Children with Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) and Synovial Sarcoma

Treatment

Hematologic
Leukemia
Lung
Miscellaneous
Small Cell

VICCHEMP1615

07/21/2016

A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects with Advanced Malignancies

Treatment

Lung

VICCTHO15129

06/07/2016

XALT3: Phase 3 Randomized Study Comparing X-396 to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients

Treatment

Lung
Non Small Cell

VICCTHO1625

06/01/2016

An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as First Line-Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)

Treatment

Lung
Small Cell

VICCTHO15117

05/19/2016

A Phase 2 Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line Treatment of Patients with Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Carcinoma (TRINITY)

Treatment

Lung
Non Small Cell

ECOGTHOS1403

04/26/2016

A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) (BI 1200.124)

Treatment

Colon
Head/Neck
Liver
Lung
Miscellaneous
Neuro-Oncology
Rectal
Sarcoma
Thyroid

VICCMD15110

04/05/2016

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Treatment

Lung
Small Cell

VICCTHO1595

03/25/2016

An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects with Relapsed Small-cell Lung Cancer after Platinum-based First Line Chemotherapy

Treatment

Colon
Head/Neck
Lung
Lymphoma
Melanoma
Non Small Cell
Ovarian
Rectal

VICCPHI1531

03/01/2016

A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers

Treatment

Lung
Non Small Cell

VICCTHO1573

02/01/2016

An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

Treatment

Colon
Esophageal
Head/Neck
Lung
Non Small Cell
Rectal

VICCPHI1598

12/10/2015

A Phase 1 Multi Arm Study Evaluating the Safety, Pharmacology and Preliminary Activity of the Co-Administration of MM-151 with seribantumab (MM-121), istiratumab (MM-141), or trametinib in biomarker-selected cancer patients

Treatment

Bladder
Breast
Colon
Esophageal
Gastric/Gastroesophageal
Gynecologic
Head/Neck
Kidney (Renal Cell)
Lung
Melanoma
Non Small Cell
Pancreatic
Rectal
Urologic
Uterine

VICCPHI1588

11/27/2015

A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors

Treatment

Lung

VICCTHO1519

10/07/2015

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti−PDL1 Antibody) Compared with Cisplatin or Carboplatin+Pemetrexed for PD-L1−Selected Chemotherapy Naive Patients with Stage Iv Non-Squamous Non−Small Cell Lung Cancer

Treatment

Lung
Non Small Cell

ECOGTHOE4512

09/15/2015

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Treatment

Breast
Lung
Pancreatic

VICCPHI1528

07/22/2015

A Multi-Center Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with MEDI4736, in Subjects with Relapsed or Refractory Solid Tumors

Treatment

Lung
Small Cell

VICCTHO1510

07/09/2015

A Phase 2 Study of MM-121 in Combination with Docetaxel or Pemetrexed versus Docetaxel or Pemetrexed Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Treatment

Lung
Non Small Cell

ECOGTHOS1400

04/02/2015

Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

Treatment

Lung
Non Small Cell

VICCTHO1443

03/11/2015

A Phase III, Randomized, Open-Label, Cross-Over, Multi-Center, Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane?) as Maintenance Treatment after Induction with Nab-Paclitaxel Plus Carboplatin in Subjects with Squamous Cell Non-Small Cell Lung Cancer (NSCLC)

Treatment

Lung

CTSUTHOS1400

01/20/2015

Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer Lung-MAP Study Targeted Treatment for Advanced Squamous Cell Lung Cancer

Treatment

Lung
Non Small Cell

VICCTHO1478

11/14/2014

A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination with Ascending Doses of Novel Therapeutics in Patients with EGFRm+ Advanced NSCLC who have progressed following therapy with an EGFR TKI (TATTON)

Treatment

Lung

ECOGTHO2511-M

11/04/2014

Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination with Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer

Treatment

Lung

THOMK3475-024-M

08/05/2014

MK3475-024 A Randomized Open-Label Phase III Trial of Pembrolizumab versus Platinum based Chemotherapy in 1L Subjects with PD-L1 Strong Metastatic Non-Small Cell Lung Cancer

Treatment

Lung
Non Small Cell

VICCTHN1244

07/25/2012

Phase 1, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of X-396 in Patients with Advanced Solid Tumors

Treatment

Non Small Cell

ECOGTHO5508-M

02/09/2011

Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC

Treatment

Lung

ECOGTHO4508-M

12/07/2010

Three-Arm Randomized Phase II Study of Carboplatin and Paclitaxel in Combination with Cetuximab, IMC-A12 or Both for Advanced Non-small Cell Lung Cancer Patients WhoWill Not Receive Bevacizumab-based Therapy

Treatment

Lung

CTSUTHOC30607-M

02/17/2010

ARandomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progressing Patients following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer

Treatment

Non Small Cell

ECOGTHOE1505-M

07/27/2007

A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (> or = 4 cm)- IIIA Non-Small Cell Lung Cancer (NSCLC)